Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic...

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells offer a promising cancer immunotherapy strategy.
• CAR-NK cells face challenges in solid tumor treatment, including limited efficacy, expansion, and persistence within the suppressive tumor microenvironment.
• IL-15 cytokine-armored CAR-NK therapeutics have been developed to enhance anti-tumor activity, but preclinical studies show significant toxicity in immunodeficient models.

Purpose of the Study:

• To investigate the efficacy and toxicity of cytokine-armored CAR-NK cells in a more physiologically relevant preclinical model.
• To address the limitations of immunodeficient mouse models in accurately assessing CAR-NK cell therapy for solid tumors.
• To establish a robust platform for evaluating CAR-NK cell therapy in the presence of a functional immune system.

Main Methods:

• Utilizing humanized mouse models engrafted with tumors to better simulate the human immune response and tumor microenvironment.
• Administering IL-15 cytokine-armored CAR-NK cells to humanized mice to assess therapeutic efficacy and potential toxicities.
• Monitoring CAR-NK cell expansion, persistence, anti-tumor activity, and systemic toxicity in the humanized model.

Main Results:

• Preclinical studies in immunodeficient mice show significant toxicity and early mortality with cytokine-armored CAR-NK cells, without clear evidence of cytokine release syndrome.
• The lack of a fully functional immune system in immunodeficient models may permit unchecked CAR-NK cell expansion, leading to observed toxicity.
• Humanized mice are hypothesized to allow for tumor engraftment and mitigate CAR-NK cell-associated toxicity, enabling effective efficacy assessment.

Conclusions:

• Cytokine-armored CAR-NK cell therapy requires careful evaluation in immunocompetent models to avoid misleading toxicity findings.
• Humanized mouse models represent a critical advancement for preclinical assessment of CAR-NK cell therapies, particularly for solid tumors.
• This approach may enable the safe and effective development of CAR-NK cell-based cancer treatments by accurately reflecting in vivo dynamics and mitigating toxicity.